


CLAIMS


What Is Claimed Is:


1. A compound, wherein the compound is:


















































































































































































































































































































































































































































































































































































































































































































































































































or


or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein the compound is:


;

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of claim 1 or 2, and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3, wherein the composition further comprises an additional bioactive agent.

5. The pharmaceutical composition of claim 4, wherein the additional bioactive agent is an anti-inflammatory agent, a chemotherapy agent, or an immunomodulatory agent.

6. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of any one of claims 3 to 5, for use in treating a disease, a disorder, or a symptom causally related to LRRK2 in a subject.

7. The compound or pharmaceutical composition for use of claim 6, wherein the disease or disorder is idiopathic Parkinson's disease (PD), LRRK2 mutation associated PD, primary tauopathies, lewy body dementia, Crohn's Disease, Leprosy, neuroinflammation, Progressive Supranuclear Palsy, Picks disease, FTDtau, TDP-43 Frontal Temporal Dementia, TDP-43 ALS, c9orf ALS, Huntington's disease, spinocerebellar ataxias (SCAs) 1, 2, 3, 6, 7, and 17, dentatorubral pallidoluysian atrophy (DRPLA), or Kennedy's disease.